Pfizer (PFE) Stock Forecast & Long-Term Predictions

• Price Today — $26.36 USD.

• Price at Q1 of 2024 — $27.75. 

• Price for next year 2025 — $20.

• Long-term price 2025-2030 — $20-$52.

Positive price momentum is expected in the coming month. Technical analysis gives a strong buy signal. According to Tipranks, the overall consensus of Wall Street analysts is Moderate Buy. The average price target for Pfizer over the next 12 months is $31.92.

On the 1MN timeframe, the technical learning indicates a strong sell rating for the asset. But there are also terms that suggest buying. At the time of writing:

• assets have appreciated in 6 of the last 10 days;

• chart is above the moving averages;

• 2 bullish candlestick patterns appear on the 1H timeframe. 

The value of the asset is close to the upper border of the moderate upward trend. The chart is close to the upper Bollinger Band. Breaking the $29.75 level will be a sign of strengthening bullish sentiment. The following support levels are $28.55 and $27.49. A breach below these levels will be a sell signal.

Among the predictions for the coming 5 years there are bullish and bearish scenarios. Expectations of price decline are based on the weaknesses of the company. They are pointed out by Aditya Shastri in his review. The key issue is the risk of losing market assets. The company has a strict pricing policy. And its research costs are lower than those of its main competitors.

The bulls point to the following positive factors:

• long history, brand recognition;

• operating in more than 180 countries;

• strong workforce, quality employee training program. 

Despite this, the company faces serious challenges in 2024. Covid's vaccine and drugs no longer contribute much to the earnings.

A phase III trial of Danugliprone was halted at the end of 2023. This is a weight loss drug that investors had big hopes for. The company's debt became greater in 2023. By March 2024, it was $68.70 billion. The reason is the cost of buying Seagen.

Even in the most optimistic scenario, the asset's value will grow only 1.6x over 5 years. Given these projections, this asset is more suitable for people looking for passive income in the form of dividends. In a bearish scenario, assets could lose over 40% and fall below $20.

Most stock analysts expect the share price to stabilize in 2024. They are confident that the company will post similar revenues in 2023. Meanwhile, net savings will grow to $2 billion.

Some experts believe that PFE shares could rise as early as 2024. This is due to plans to reduce debt and improve operating margins. 

Leading analyst target prices:

• $29 — Morgan Stanley;

• $32 — TD Cowen;

• $36 — BMO Capital Markets;

• $45 — Cantor Fitzgerald.

Expectations for 2025 are represented by many services. The target prices are lower than the predictions of Wall Street analysts for 2024. It is also unlikely that the issuer's revenues and earnings will reach 2021-2022 levels.

The main growth driver for the financial results will be the contribution from Seagen. In addition, PFE is expected to launch new products.

End 2025 target levels:

• $28.43 — LongForecast;

• $29.16 — Coincodex;

• $33.06 — Stockraven;

• $35.01 — CoinPriceForecast.

Analysts are divided on the future of Pfizer. Bulls expect the release of new products in demand. This will lead to improved financial performance. Bears believe that the company will not be able to beat 2021-2022 sales in the coming years.

In accord with the Stock Analysis Service, 2026 sales will be in the range of $59.4 billion to $69.2 billion. This is down from the 2022 level of $100.33 billion. Expected EPS is $2.47-$3.71.

Potential end-2026 asset value:

• $29.80 — Coincodex;

• $33.58 — LongForecast;

• $35.44 — Stockraven;

• $38.05 — CoinPriceForecast.

According to the stock testing, EPS will be between $2.43 and $3.73 in 2027. Even in the maximum scenario, this result is lower than in 2021-2022. But exceeds the 2023 level. 

Many experts are optimistic. They believe that prices in 2027 will be more expensive than the current price. Their reasoning is on the basis of investors' desire for riskier assets. Against the background of lower interest rates, the asset market will receive an inflow of liquidity.

Target prices for 2027:

• $20.84 — LongForecast;

• $30.45 — Coincodex;

• $39.75 — CoinPriceForecast;

• $40.28 — Stockraven;

• $43.08 — Stockscan.

The bears expect the capitalization to be lower in 5 years than it is now. They point out that the company spends less on research than its peers. This means that new drugs may be delayed.

Bulls claim the company has one of the top distribution networks among pharmaceutical companies worldwide. This is a major benefit. The most positive projection for 2028 promises a 60% growth in prices compared to early June 2024 levels.

Expected end-2028 asset price:

• $17.51 — LongForecast;

• $30.53 — Stockscan;

• $31.11 — Coincodex;

• $40.94 — Stockraven;

• $46.67 — CoinPriceForecast.